Document Detail


Is discontinuation of hormone replacement therapy possible for patients with late-onset hypogonadism?
MedLine Citation:
PMID:  18479356     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
OBJECTIVE: The first-line treatment for late-onset hypogonadism (LOH) is hormone replacement therapy (HRT). However, whether lifetime HRT is necessary has not been settled. We evaluated LOH-related symptoms and endocrinologic values after discontinuation of HRT in patients with LOH who had benefited from it. METHODS: Twenty-five men (mean age 54.2 years, range 40-73) in whom HRT had been effective and who were available for follow-up 3 months after the discontinuation of HRT were studied. LOH-related symptoms were judged according to the Aging Males' Symptoms (AMS) scale and other questionnaires. Laboratory and endocrinologic values and LOH-related symptoms were assessed before HRT, at the end of HRT, and 3 months after its discontinuation. RESULTS: Serum testosterone levels increased significantly with HRT. However, they returned to the pretreatment levels after discontinuation of HRT. The total AMS score decreased significantly after HRT, and a significant improvement was maintained 3 months after discontinuation. The somatovegetative and psychological subscores of the AMS also improved, although the sexual subscore did not change significantly. A slight improvement was also observed in the short version of the International Index of Erectile Function (IIEF-5) score and the Self-rating Depression Scale (SDS) score after HRT. However, changes in these scores did not reach statistical significance. No other changes in the endocrinologic profile and no severe adverse effects were seen. CONCLUSIONS: Improvement in symptoms may remain after discontinuation of HRT in patients with LOH even though their endocrinologic status declines. Our findings may encourage physicians to discontinue HRT if LOH-related symptoms have improved after several months of HRT.
Authors:
Akira Tsujimura; Shingo Takada; Yasuhiro Matsuoka; Toshiaki Hirai; Tetsuya Takao; Yasushi Miyagawa; Norio Nonomura; Akihiko Okuyama
Related Documents :
15705376 - N-acetyl-cysteine is a novel adjuvant to clomiphene citrate in clomiphene citrate-resis...
8034076 - Post-therapeutic evolution of serum chlamydial antibody titers in women with acute salp...
15840746 - Prospective parallel randomized, double-blind, double-dummy controlled clinical trial c...
19131846 - New equol supplement for relieving menopausal symptoms: randomized, placebo-controlled ...
21940766 - Race and sex differences in response to endothelin receptor antagonists for pulmonary a...
9265916 - Dosing the antipsychotic medication olanzapine.
Publication Detail:
Type:  Journal Article     Date:  2008-05-08
Journal Detail:
Title:  International journal of urology : official journal of the Japanese Urological Association     Volume:  15     ISSN:  1442-2042     ISO Abbreviation:  Int. J. Urol.     Publication Date:  2008 Jul 
Date Detail:
Created Date:  2008-09-12     Completed Date:  2008-12-18     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9440237     Medline TA:  Int J Urol     Country:  Australia    
Other Details:
Languages:  eng     Pagination:  625-9     Citation Subset:  IM    
Affiliation:
Department of Urology, Osaka University Graduate School of Medicine, Suita, Japan. akitsuji@uro.med.osaka-u.ac.jp
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Aged
Chorionic Gonadotropin / administration & dosage*
Hormone Replacement Therapy*
Humans
Hypogonadism / blood,  drug therapy*
Male
Middle Aged
Testosterone / administration & dosage*
Chemical
Reg. No./Substance:
0/Chorionic Gonadotropin; 58-22-0/Testosterone

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Reclassification of the current tumor, node, metastasis staging in pT3 renal cell carcinoma.
Next Document:  Intraoperative real time three-dimensional transesophageal echocardiographic evaluation of right atr...